Table 5 Characteristics at baseline by treatment group in the overall study sample, and cohorts weighted on sIPTW and odds

Sex^a

4%

1%

1%

  Female

1451 (73%)

2247 (71%)

71%

72%

73%

73%

  Male

538 (27%)

912 (29%)

29%

28%

27%

27%

Age at treatment start^b

36.6 (29.3; 43.9)

38.5 (31.6; 45.4)

13%

37.6 (30.4–45.2)

37.9 (30.7–44.8)

2%

36.6 (29.3–43.9)

36.8 (29.8–43.9)

1%

MS duration at treatment^b

6.3 (2.4; 11.8)

7.4 (3.6; 13.0)

13%

6.8 (2.7–12.9)

7.0 (3.2–12.4)

2%

6.2 (2.4–11.8)

6.2 (2.7–11.6)

1%

EDSS at treatment start^a

32%

12%

7%

  2 or less

434 (22%)

1122 (35%)

26%

31%

22%

23%

  Between 2 and 4

981 (49%)

1403 (44%)

50%

45%

49%

46%

  4 or more

574 (29%)

634 (20%)

24%

24%

29%

31%

Number of relapses in the previous 12 months^a

37%

4%

3%

  0

570 (29%)

1287 (41%)

35%

36%

29%

29%

  1

752 (38%)

1269 (40%)

39%

39%

38%

37%

  2

484 (24%)

491 (15%)

20%

18%

24%

23%

  3 or more

183 (9%)

112 (3%)

6%

6%

9%

10%

Number of previous MS treatments^a

17%

15%

14%

  0

401 (20%)

435 (14%)

19%

14%

20%

15%

  1

924 (46%)

1635 (52%)

46%

52%

46%

52%

  2

457 (23%)

730 (23%)

23%

23%

23%

23%

  3 or more

207 (10%)

359 (11%)

12%

11%

10%

10%

MS activity in the previous 12 months^a

29%

3%

3%

  None

410 (21%)

1028 (32%)

26%

28%

21%

20%

  Worsening

160 (8%)

259 (8%)

8%

8%

8%

9%

  Relapse

886 (44%)

1273 (40%)

42%

42%

44%

43%

  Relapse and worsening

533 (27%)

599 (19%)

23%

22%

27%

27%

Data source^a

28%

1%

8%

  MS Base

1141 (57%)

2152 (68%)

30%

29%

57%

53%

  DMSR

607 (30%)

837 (26%)

62%

62%

30%

34%

  OFSEP

241 (12%)

170 (5%)

8%

8%

12%

13%